Blanco O, Lugones Y, Monzote L, Faure R, Salomao R, Pérez J, Díaz E, Cruz A, Ospina OL, López-Rodríguez E

Language: English
References: 11
Page: 4501-4504
PDF size: 244.03 Kb.

ABSTRACT

The understanding of the correlation between the biophysical processes mediating the activity of clinically introduced surfactants is essential for their clinical efficacy, together with their simultaneous impact on coexistent respiratory infections. Therefore, this study was aimed to characterize the interfacial and structural properties of the films formed by Surfacen® and how they could mediate the drug efficacy of this surfactant as a stabilizer of the respiratory air-liquid interface. Moreover, the rheological properties and particle size were also studied, and the product’s anti-inflammatory effect against the respiratory pathogen Staphylococcus aureus and also Leishmania amazonensis were assessed in pharmacological studies in vitro. Surfacen® displayed similar properties as those of an endogenous surfactant and an organic extract, by forming stable and efficient film-active surfaces in the air-liquid interface. Its effect was characterized by a much higher segregation of lipid condensed phases, with significantly larger and more stable ordered domains when subjected to compression, its increased mechanical stability relevant for respiratory dynamics. All these results are relevant for the optimization of surfactants by stabilizing its film-forming properties. Significantly, Surfacen® showed a low viscosity, which is attractive for the intratracheal administration, and simultaneously inhibited the release of pro-inflammatory cytokines (TNF-a and IL-6) from monocytes and neutrophils stimulated with S. aureus. Moreover, Surfacen® and SP-A were active against L. amazonensis, this response enhanced by combining both, constituting the first report of the antileishmanial activity of a pulmonary surfactant-SP-A combination, as a potential therapeutic strategy. This research granted the 2015 Award of the Cuban National Academy of Sciences.

REFERENCES

1. Keating E, Waring AJ, Walther FJ, Possmayer F, Veldhuizen RA, Petersen NO. A ToF-SIMS study of the lateral organization of lipids and proteins in pulmonary surfactant systems. Biochim Biophys Acta. 2011;1808(3):614-21.

2. Bersani I, Kunzmann S, Speer CP. Immunomodulatory properties of surfactant preparations. Expert Rev Anti Infect Ther. 2013;11(1):99-110.

3. Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol. 2005;42(3):279-87.

4. Ryan MA, Akinbi HT, Serrano AG, Perez-Gil J, Wu H, McCormack FX, et al. Antimicrobial activity of native and synthetic surfactant protein B peptides. J Immunol. 2006;176(1):416-25.

5. Perez-Cordero JJ, Lozano JM, Cortes J, Delgado G. Leishmanicidal activity of synthetic antimicrobial peptides in an infection model with human dendritic cells. Peptides. 2011;32(4):683-90.

6. Schoel WM, Schurch S, Goerke J. The captive bubble method for the evaluation of pulmonary surfactant: surface tension, area, and volume calculations. Biochim Biophys Acta. 1994;1200(3):281-90.

7. Blanco O, Cruz A, Ospina OL, Lopez-Rodriguez E, Vazquez L, Perez-Gil J. Interfacial behavior and structural properties of a clinical lung surfactant from porcine source. Biochim Biophys Acta. 2012;1818(11):2756-66.

8. Lugones Y, Blanco O, Santos SS, Brunialti MK, Faure R, Salomao R. Effect of natural porcine surfactant in Staphylococcus aureus induced pro-inflammatory cytokines and reactive oxygen species generation in monocytes and neutrophils from human blood. Int Immunopharmacol. 2014;21(2):369-74.

9. Blanco O, Lugones Y, Diaz E, Monzote L. In vitro activity of the clinical pulmonary surfactant Surfacen(R) against Leishmania amazonensis. Rev Inst Med Trop Sao Paulo. 2011;53(4):235-8.

10. Lugones Y, Blanco O, Faure R, Monzote L. In vitro activity of Surfactant Protein A against Leishmania amazonensis. Biotecnología Aplicada. 2012;29:35-7.

11. Lugones Y, Blanco O, Faure R, Fidalgo LM. In vitro interaction between SURFACEN(R) and surfactant protein A against Leishmania amazonensis. Chemotherapy. 2013;59(4):247-50.